Cluster Headache Syndrome - Pipeline Review, H1 2018
Cluster Headache Syndrome - Pipeline Review, H1 2018
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cluster Headache Syndrome - Pipeline Review, H1 2018, provides an overview of the Cluster Headache Syndrome (Central Nervous System) pipeline landscape.
Cluster headache is pain that occurs along one side of the head. It is frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain, red eye, runny nose, excessive tearing and flushed face. Risk factors include age and gender. Treatment includes anti-inflammatory (steroid) medicines and triptans.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cluster Headache Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cluster Headache Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cluster Headache Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Cluster Headache Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cluster Headache Syndrome - Pipeline Review, H1 2018, provides an overview of the Cluster Headache Syndrome (Central Nervous System) pipeline landscape.
Cluster headache is pain that occurs along one side of the head. It is frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain, red eye, runny nose, excessive tearing and flushed face. Risk factors include age and gender. Treatment includes anti-inflammatory (steroid) medicines and triptans.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cluster Headache Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cluster Headache Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cluster Headache Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Cluster Headache Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cluster Headache Syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cluster Headache Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cluster Headache Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cluster Headache Syndrome (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cluster Headache Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Cluster Headache Syndrome - Overview
Cluster Headache Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cluster Headache Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cluster Headache Syndrome - Companies Involved in Therapeutics Development
Center Laboratories Inc
Crossject SA
Eli Lilly and Co
Novartis AG
Teva Pharmaceutical Industries Ltd
TrioxBio Inc
Cluster Headache Syndrome - Drug Profiles
fremanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galcanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTR-108 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pasireotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
psilocybin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sumatriptan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
verapamil hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zucapsaicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cluster Headache Syndrome - Dormant Projects
Cluster Headache Syndrome - Product Development Milestones
Featured News & Press Releases
Sep 06, 2017: Lilly To Present New Data For Galcanezumab At The 18th Congress Of The International Headache Society
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Cluster Headache Syndrome - Overview
Cluster Headache Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cluster Headache Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cluster Headache Syndrome - Companies Involved in Therapeutics Development
Center Laboratories Inc
Crossject SA
Eli Lilly and Co
Novartis AG
Teva Pharmaceutical Industries Ltd
TrioxBio Inc
Cluster Headache Syndrome - Drug Profiles
fremanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galcanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTR-108 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pasireotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
psilocybin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sumatriptan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
verapamil hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zucapsaicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cluster Headache Syndrome - Dormant Projects
Cluster Headache Syndrome - Product Development Milestones
Featured News & Press Releases
Sep 06, 2017: Lilly To Present New Data For Galcanezumab At The 18th Congress Of The International Headache Society
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Cluster Headache Syndrome, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Cluster Headache Syndrome - Pipeline by Center Laboratories Inc, H1 2018
Cluster Headache Syndrome - Pipeline by Crossject SA, H1 2018
Cluster Headache Syndrome - Pipeline by Eli Lilly and Co, H1 2018
Cluster Headache Syndrome - Pipeline by Novartis AG, H1 2018
Cluster Headache Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018
Cluster Headache Syndrome - Pipeline by TrioxBio Inc, H1 2018
Cluster Headache Syndrome - Dormant Projects, H1 2018
Number of Products under Development for Cluster Headache Syndrome, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Cluster Headache Syndrome - Pipeline by Center Laboratories Inc, H1 2018
Cluster Headache Syndrome - Pipeline by Crossject SA, H1 2018
Cluster Headache Syndrome - Pipeline by Eli Lilly and Co, H1 2018
Cluster Headache Syndrome - Pipeline by Novartis AG, H1 2018
Cluster Headache Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018
Cluster Headache Syndrome - Pipeline by TrioxBio Inc, H1 2018
Cluster Headache Syndrome - Dormant Projects, H1 2018
LIST OF FIGURES
Number of Products under Development for Cluster Headache Syndrome, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Center Laboratories Inc
Crossject SA
Eli Lilly and Co
Novartis AG
Teva Pharmaceutical Industries Ltd
TrioxBio Inc
Number of Products under Development for Cluster Headache Syndrome, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Center Laboratories Inc
Crossject SA
Eli Lilly and Co
Novartis AG
Teva Pharmaceutical Industries Ltd
TrioxBio Inc
